CagriSema (Cagrilintide + Semaglutide)
Also known as: CagriSema, Cagrilintide/semaglutide, Cagri-Sema
Investigational once-weekly combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide. Under FDA review for obesity; not approved.
Last updated
Mechanism of Action
CagriSema co-administers two long-acting peptides in one weekly injection. Semaglutide activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying and reducing appetite through hypothalamic and brainstem signaling. Cagrilintide is a long-acting amylin analog that activates amylin and calcitonin receptors in the area postrema and hypothalamus, adding satiety signaling through a separate pathway. The two mechanisms are complementary, which is the rationale for combining them.
- Half-life
- ~1 week (both components)
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Studied for chronic weight management in adults with obesity or overweight (REDEFINE 1)
- Studied for weight loss in adults with obesity and type 2 diabetes (REDEFINE 2)
- Studied for glycemic control in type 2 diabetes (REIMAGINE program)
Potential Side Effects
- Nausea, vomiting, diarrhea and constipation, mostly during dose escalation
- Decreased appetite and fatigue
- Gallbladder events
- Injection-site reactions
- Class concerns for GLP-1 agonists (pancreatitis; thyroid C-cell tumors in rodents)
Common Dosing
No approved dose; phase 3 trials used cagrilintide 2.4 mg plus semaglutide 2.4 mg subcutaneously once weekly, reached after a gradual dose-escalation period of about 16 weeks. If approved, dosing would be set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
- Semaglutide component: personal or family history of medullary thyroid carcinoma or MEN 2
- Pregnancy (not studied; weight-loss drugs are generally avoided)
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
Semaglutide
A long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Among the most effective approved weight-loss therapies.
- View
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025
- View
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
2025
- View
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
2026